AbbVie stock shows range-bound action supported by MACD bullish structure: weekly forecast

Traders Union
All News
Financial News
AbbVie slips 0.50% this week

Highlights

ABBV remains in a strong bullish trend, trading significantly above all major medium- and long-term moving averages.
Oscillators indicate overbought conditions and mixed momentum, with both bullish bias and emerging signs of trend indecision.
Expected 7-day range is $250.33 to $263.51; price consolidates near highs with equal upside and downside probabilities, critical levels at $255.99 and $250.

Pipeline breakthroughs and M&A drive positive sentiment this week

AbbVie received a key U.S. FDA approval for Skyrizi, expanding its use to children six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis and introducing a new pediatric formulation. The company also secured a positive EMA opinion recommending RINVOQ for severe alopecia areata and non-segmental vitiligo in Europe, supported by positive phase 3 clinical results. Additionally, AbbVie reported statistically significant phase 3 results for an epcoritamab and lenalidomide combination in lymphoma and announced a $10.9 billion agreement to acquire Apogee Therapeutics to strengthen its immunology pipeline.

Mixed momentum signals amid overbought weekly technicals

On the weekly timeframe, ABBV continues to trade significantly above its key moving averages, with the MA-20 and MA-50 offering the closest dynamic supports far below current levels. Momentum indicators are mixed: the MACD remains bullish, while the ADX at 14.54 signals trend indecision. Weekly oscillators, including the RSI and Commodity Channel Index, point to overbought conditions, echoed by extreme readings on the Bull/Bear Power and Stochastic RSI. Support for the week is seen around $250, with resistance near $255.99 and volatility at 9.94%, indicating consolidation near highs amid some early signs of divergence.

Sideways bias as consolidation and breakout risks shape next week

For the next five trading days, ABBV is expected to consolidate within a $250.33 to $263.51 range, with a roughly equal likelihood of upside or downside. A sustained move above $255.99 would confirm a bullish breakout toward the weekly high, while a drop below $250 could trigger further profit-taking and a move closer to dynamic support levels. Given overbought weekly momentum alongside mixed trend signals, the base case is sideways action near current levels, with occasional swings tied to technical triggers.

Previously it was reported that AbbVie’s robust price momentum was fueled by strategic advances, with analysts highlighting the potential for either sustained breakout or increased volatility. The stock’s resilience above key moving averages, aligned with new regulatory milestones and an expanding immunology pipeline, underscores a prevailing consolidation phase near highs, with traders advised to monitor $250 and $255.99 as pivotal levels for directional confirmation.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.